Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Alan Boddy.

Newcastle AuthorsTitleYearFull text
Professor Gareth Veal
Julieann Sludden
Dr David Jamieson
Julie Errington
Dr Ghada Malik
et al.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma2016
Chris Walsh
Dr Jennifer Bonner
Professor Alan Boddy
Professor Gareth Veal
Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer2016
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al.
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Professor Andrew Pearson
Dr Quentin Campbell Hewson
Professor Alan Boddy
Melanie Griffin
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study2015
Professor Alan Boddy
Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer2015
Dr James Murray
Julieann Sludden
Professor Alan Boddy
Professor Nicola Curtin
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System2015
Professor Alan Boddy
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study2014
Dr Anthony Oxley
Philip Berry
Gordon Taylor
Dr Joe Cowell
Dr Michael Hall
et al.
An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion and vitamin A status in humans2014
Dr Chris Hill
Julie Errington
Dr Ghada Malik
Professor Alan Boddy
Professor Gareth Veal
et al.
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer2014
Barry Dent
Dr Rachel O'Donnell
Laura Ogle
Padmini Ramesh
Nick Hayes
et al.
Detection and characterization of circulating tumor cells by imaging flow cytometry2014
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Dr Hyun Jin Park
Professor Georg Lietz
Dr Anthony Oxley
Professor Alan Boddy
Philip Berry
et al.
Simplified approaches for estimating vitamin A stores and β-carotene bioconversion in humans2014
Professor Alan Boddy
Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples2014
Professor Gareth Veal
Julie Errington
Sophie Rowbotham
Nicola Illingworth
Dr Ghada Malik
et al.
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma2013
Christopher Hill
Dr David Jamieson
Huw Thomas
Dr Colin Brown
Professor Alan Boddy
et al.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo2013
Dr Anthony Oxley
Philip Berry
Professor John Hesketh
Professor Alan Boddy
Professor Georg Lietz
et al.
Gender differences in retinol metabolism are independent of β-carotene bioconversion2013
Professor Alan Boddy
Genetics of Cisplatin Ototoxicity: Confirming the Unexplained?2013
Professor Gareth Veal
Julie Errington
Dr Ghada Malik
Dr Chris Hill
Professor Alan Boddy
et al.
Investigating the pharmacokinetics and dosing of anticancer drugs in infants and young children2013
Professor Alan Boddy
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years2013
Professor Alan Boddy
Dr Alison Steel
The European Paediatric Oncology off-patent medicines Consortium (EPOC) pharmacokinetic/pharmacodynamic study of doxorubicin2013
Professor Gareth Veal
Professor Alan Boddy
Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring2012
Professor Gareth Veal
Professor Alan Boddy
Chemotherapy in newborns and preterm babies2012
Professor Alan Boddy
Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration2012
Dr Emma Meczes
Huw Thomas
Professor Richard Edmondson
Professor Gareth Veal
Professor Alan Boddy
et al.
Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours2012
Professor Ruth Plummer
Professor Alan Boddy
Julieann Sludden
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours2011
Professor Alan Boddy
Professor Ann Daly
Professor Gareth Veal
Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases2011
Professor Alan Boddy
Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example2011
Dr David Jamieson
Professor Alan Boddy
Pharmacogenetics of genes across the doxorubicin pathway2011
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Mike Cole
Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy2011
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Mike Cole
Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients2011
Sue Green
Professor Alan Boddy
Dr Steven Cruickshank
The Birmingham Boron Neutron Capture Therapy (BNCT) Project: Developments towards Selective Internal Particle Therapy [abstract]2011
Dr Simon Pridgeon
Professor Rakesh Heer
Gordon Taylor
Professor Herbie Newell
Kieran O'Toole
et al.
Thiothymidine combined with UVA as a potential novel therapy for bladder cancer2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Melanie Griffin
Professor Alan Boddy
Professor Andrew Pearson
Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia2010
Professor Alan Boddy
Boron neutron capture therapy (BNCT): Clinical optimization of uptake parameters of boronphenyllalanine (BPA)2010
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Mike Cole
Professor Alan Boddy
Professor Gareth Veal
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate2010
Professor Gareth Veal
Julie Errington
Professor Andrew Pearson
Professor Alan Boddy
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients2010
Sophie Rowbotham
Professor Alan Boddy
Dr Chris Redfern
Professor Gareth Veal
Professor Ann Daly
et al.
Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation2010
Sophie Rowbotham
Professor Ann Daly
Professor Gareth Veal
Professor Alan Boddy
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.
[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Professor Alan Boddy
A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT2009
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma2009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma2009
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies2008
Mike Cole
Professor Alan Boddy
Dr Michael Keir
Professor Gareth Veal
Estimation of renal function and its potential impact on carboplatin dosing in children with cancer2008
Professor Ruth Plummer
Dr Christopher Jones
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors2008
Professor Gareth Veal
Professor Alan Boddy
Population pharmacokinetic investigation of actinomycin D in children and young adults2008
Dr Patricia Turner
Mike Cole
Michael Batey
Sandra Beare
Professor Alan Boddy
et al.
Reduced folate carrier single nucleotide polymorphism associated with methotrexate clearance in breast cancer patients2008
Mike Cole
Annie Parry
Dr Michael Reid
Professor Alan Boddy
Professor Gareth Veal
et al.
A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer2007
Professor Gareth Veal
Julie Errington
Dr Michael Tilby
Professor Alan Boddy
Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours2007
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed2007
Professor Alan Boddy
Melanie Griffin
Julie Errington
Professor Gareth Veal
Dosing of cancer patients with low or absent renal function2007
Dr Michael Keir
Mike Cole
Annie Parry
Professor Alan Boddy
Professor Gareth Veal
et al.
Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing2007
Dr Jane Renwick
Gordon Taylor
Huw Thomas
Professor Alan Boddy
Dr Chris Redfern
et al.
Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo2007
Dr David Jamieson
Kerrie Wilson
Dr Simon Pridgeon
Dr Jane Margetts
Professor Richard Edmondson
et al.
NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism2007
Professor Alan Boddy
Paclitaxel poliglumex. Antimitotic drug, Oncolytic.
2007
Professor Alan Boddy
Paclitaxel poliglumex: Antimitotic drug oncolytic2007
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Professor Gareth Veal
Mike Cole
Geoffrey Taylor
Julie Errington
Professor Alan Boddy
et al.
Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients2007
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Professor Herbie Newell
Professor Stephen O'Brien
et al.
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia2007
Professor Gareth Veal
Mike Cole
Julie Errington
Professor Alan Boddy
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group2007
Professor Gareth Veal
Sophie Rowbotham
Professor Alan Boddy
Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma2007
Professor Alan Calvert
Professor Alan Boddy
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group2007
Professor Steven Clifford
Rachel Daniel
Dr Agata Rozanska
Huw Thomas
Professor Alan Boddy
et al.
Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma2007
Professor Gareth Veal
Julie Errington
Huw Thomas
Professor Alan Boddy
Biliary excretion of etoposide in children with cancer2006
Dr Jo Lee
Julieann Sludden
Professor Alan Boddy
Dr Mark Verrill
Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.2006
Mike Cole
Professor Alan Boddy
Dr Pamela Kearns
Lisa Price
Annie Parry
et al.
Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?2006
Professor Alan Boddy
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy2006
Dr David Jamieson
Professor Alan Boddy
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor2006
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Dr Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Professor Ruth Plummer
Professor Alan Boddy
Professor Nicola Curtin
Professor Herbie Newell
Lynsey Robson
et al.
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide2005
Dr Jane Renwick
Professor Alan Boddy
Dr Chris Redfern
Professor Andrew Pearson
Professor Gareth Veal
et al.
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells2005
Annie Parry
Dr Michael Tilby
Professor Dianne Ford
Emerita Professor Suzanne Cholerton
Professor Andrew Pearson
et al.
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer2005
Professor Gareth Veal
Mike Cole
Julie Errington
Annie Parry
Dr Juliet Hale
et al.
Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study2005
Dr Ashraf Azzabi
Dr Andrew Hughes
Dr Paula Calvert
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations2005
Professor Ruth Plummer
Dr Christopher Jones
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-12005
Professor Andrew Pearson
Professor Alan Boddy
Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma2004
Mike Cole
Annie Parry
Dr Michael Keir
Professor Andrew Pearson
Professor Alan Boddy
et al.
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics2004
Professor Gareth Veal
Professor Alan Boddy
Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy2004
Professor Alan Boddy
Gordon Taylor
Dr Andrew Hughes
Professor Alan Calvert
Professor Herbie Newell
et al.
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG3372003
Professor Gareth Veal
Dr Sally Coulthard
Professor Alan Boddy
Chemotherapy individualization2003
Professor Gareth Veal
Julie Errington
Julieann Sludden
Melanie Griffin
Annie Parry
et al.
Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Julie Errington
Professor Gareth Veal
Julieann Sludden
Melanie Griffin
Professor Andrew Pearson
et al.
Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Justin Armstrong
Professor Gareth Veal
Dr Chris Redfern
Professor Alan Boddy
Effects of ketoconazole and acitretin on retinoid isomerisation and metabolism in neuroblastoma2003
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Professor Gareth Veal
Julie Errington
Professor Andrew Pearson
Professor Alan Boddy
Poster Presentation: Oxidative metabolism of 13-cis-retinoic acid in children with neuroblastoma2003
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
Potentiation of raltitrexed (RTX) in vitro by thymidine phosphorylase (TP) and TP distribution in vivo2003
Professor Gareth Veal
Julie Errington
Dr Chris Redfern
Professor Andrew Pearson
Professor Alan Boddy
et al.
Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells2002
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma2002
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)2002
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 2002
Huw Thomas
Mike Cole
Suzanne Elliott
Professor Herbie Newell
Professor Alan Calvert
et al.
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide2002
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
The in vivo distribution of a CEA directed antibody conjugated to thymidine phosphorylase2002
Dr Andrew Simpson
Dr Paula Calvert
Julieann Sludden
Professor Alan Boddy
Melanie Griffin
et al.
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules2002
Professor Gareth Veal
Melanie Griffin
Annie Parry
Dr Juliet Hale
Professor Andrew Pearson
et al.
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin2001
Professor Herbie Newell
Professor Alan Boddy
Geoffrey Taylor
Andrew Johnston
Professor Andrew Pearson
et al.
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation2001
Professor Alan Boddy
All half-lives are wrong, but some half-lives are useful2001
Dr Ian Sharkey
Professor Alan Boddy
Body surface area estimation in children using weight alone: Application in paediatric oncology2001
Professor Alan Boddy
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children2001
Mike Cole
Professor Andrew Pearson
Professor Alan Boddy
Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion2001
Professor Alan Boddy
Dr Martin Highley
Dr John Fenwick
Professor Alan Calvert
Estimation of glomerular filtration rate in cancer patients2001
Professor Gareth Veal
Dr Cinera Dias
Annie Parry
Julie Errington
Dr Juliet Hale
et al.
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy2001
Professor Gareth Veal
Julie Errington
Dr Chris Redfern
Professor Andrew Pearson
Professor Alan Boddy
et al.
Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Dr Xiaohong Lu
Julie Errington
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines2000
Dr Andrew Hughes
Melanie Griffin
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel2000
Melanie Griffin
Professor Alan Boddy
Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients2000
Melanie Griffin
Professor Alan Boddy
Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients2000
Professor Gareth Veal
Dr Cinera Dias
Professor Alan Boddy
Annie Parry
Dr Juliet Hale
et al.
In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children2000
Professor Alan Boddy
Metabolism and pharmacokinetics of oxazaphosphorines2000
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
Huw Thomas
Professor Alan Calvert
Professor Alan Boddy
Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours2000
Huw Thomas
Professor Alan Boddy
Professor Andrew Pearson
Professor Herbie Newell
Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial2000
Professor Alan Boddy
Gordon Taylor
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration1999
Professor Alan Calvert
Dr Martin Highley
Professor John Lunec
Professor Alan Boddy
Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene1999
Mike Cole
Professor Andrew Pearson
Professor Alan Boddy
Cyclophosphamide metabolism in children with Fanconi's anaemia1999
Dr Andrew Hughes
Melanie Griffin
Professor Alan Calvert
Professor Herbie Newell
Professor Alan Boddy
et al.
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days1999
Michael Batey
Kevin Fishwick
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
et al.
Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer1999
Professor Gareth Veal
Professor Alan Boddy
Huw Thomas
Annie Parry
Professor Andrew Pearson
et al.
Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy1999
Professor Alan Boddy
Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients1999
Mike Cole
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Andrew Pearson
Professor Alan Boddy
et al.
The effect of fluconazole on cyclophosphamide metabolism in children1999
Mike Cole
Professor Andrew Pearson
Professor Alan Boddy
Cyclophosphamide metabolism in children with Fanconi's anaemia1998
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
Andrew Johnston
Professor Andrew Pearson
et al.
Deoxyuridine plasma levels during the phase I study of nolatrexed in children with advanced cancer1998
Professor Alan Boddy
Huw Thomas
High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours1998
Dr Andrew Hughes
Melanie Griffin
Professor Alan Calvert
Andrew Johnston
Professor Herbie Newell
et al.
Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ TM) and paclitaxel in patients with advanced solid tumours1998
Professor Alan Boddy
Melanie Griffin
Dr Margaret Little
Professor Andrew Pearson
Pharmacokinetics and blood distribution in paediatric patients of SPI-77: Cisplatin encapsulated in Stealth® liposomes1998
Professor Alan Boddy
Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer1998
Professor Alan Boddy
Gordon Taylor
Professor Herbie Newell
Professor Alan Calvert
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors1998
Huw Thomas
Professor Alan Boddy
Professor Andrew Pearson
Professor Herbie Newell
Validation of pharmacologically-guided dosing of carboplatin in paediatric patients1998
Professor Alan Boddy
Huw Thomas
Lynsey Robson
Professor Alan Calvert
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer1997
Professor Alan Boddy
Professor Andrew Pearson
Dr Michael Tilby
Professor Herbie Newell
Cisplatin pharmacokinetics in children with cancer1997
Professor Andrew Pearson
Professor Alan Boddy
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children1997
Professor Alan Boddy
Pharmacogenetics in cancer etiology and chemotherapy1997
Dr Michael Tilby
Professor Andrew Pearson
Professor Alan Boddy
Professor Herbie Newell
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy1997
Professor Alan Boddy
Huw Thomas
RMP-7. Potential as an adjuvant to the drug treatment of brain tumours1997
Professor Steve Wedge
Fiona Chapman
Gordon Taylor
Huw Thomas
Professor Alan Boddy
et al.
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid1996
Professor Alan Boddy
Mike Cole
Professor Andrew Pearson
Cyclophosphamide pharmacokinetics in children1996
Professor Alan Boddy
Huw Thomas
Professor Herbie Newell
Professor Alan Calvert
Lynsey Robson
et al.
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study1996
Professor Alan Boddy
Professor Andrew Pearson
Professor Roderick Skinner
Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics1996
Professor Alan Boddy
Professor Andrew Pearson
Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration1996
Professor Alan Boddy
Professor Andrew Pearson
Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration1996
Professor Alan Boddy
Professor Herbie Newell
Professor Andrew Pearson
Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis1996
Professor Alan Boddy
Professor Andrew Pearson
Professor Herbie Newell
Population pharmacokinetics of carboplatin in children1996
Professor Alan Boddy
Professor Andrew Pearson
Comparison of continuous infusion and bolus administration of ifosfamide in children
1995
Professor Alan Boddy
Mike Cole
Professor Andrew Pearson
Professor Herbie Newell
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
1995
Professor Alan Boddy
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients
1995
Professor Alan Calvert
Professor Alan Boddy
Dr Andrew Hughes
Lynsey Robson
Huw Thomas
et al.
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.1995
Gordon Taylor
Professor Alan Boddy
Professor Alan Calvert
Andrew Johnston
Professor Herbie Newell
et al.
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion1995
Professor Steve Wedge
Gordon Taylor
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement1995
Professor Alan Boddy
Mike Cole
Professor Andrew Pearson
Cyclophosphamide Metabolism in Children1995
Professor Alan Boddy
Mike Cole
Professor Andrew Pearson
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion1995
Professor Alan Boddy
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Andrew Pearson
Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide1994
Professor Alan Boddy
Professor Andrew Pearson
Dr Michael Tilby
Professor Herbie Newell
The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.1994
Dr Hilary Wynne
Professor Alan Boddy
The Association of Age and Frailty with the Pharmacokinetics and Pharmacodynamics of Metoclopramide1993
Professor Alan Boddy
Professor Andrew Pearson
Pharmacokinetics and Metabolism of Ifosfamide Administered as a Continuous Infusion in Children1993
Professor Andrew Pearson
Professor Alan Boddy
Reproducibility of Methods Relating to Cyclophosphamide Metabolic Studies; response
1993
Professor Alan Boddy
The role of pharmacogenetics in chemotherapy: modulation of tumor response and host toxicity1993
Professor Alan Boddy
Combined thin-layer chromatography—photography—densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma
1992
Professor Alan Boddy
Comparative anticonvulsant potency and pharmacokinetics of (+)- and (−)-enantiomers of stiripentol
1992
Professor Alan Boddy
Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide1992
Professor Alan Boddy
Professor Andrew Pearson
Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients1992
Professor Alan Boddy
Emerita Professor Suzanne Cholerton
Professor Ann Daly
Professor Janice Ellis
Julian Leathart
et al.
The pharmacogenetics of chemical carcinogenesis1992
Professor Alan Boddy
Application of a linear recirculation model to drug targeting1991
Professor Alan Boddy
Introduction: Abstracts of poster presentations: Polymorphic Urinary Metabolite Profile of Cyclophosphamide in Turkish Patients1991